(Nasdaq:PGNX) Progenics Pharmaceuticals, Inc. Hits 52 Week Low

0
7
Stranded freeimages.com/stephie
Stranded freeimages.com/stephie

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX)

December 5th, 2018
Amidst falling markets Progenics Pharmaceuticals, Inc. fell $0.38 Tuesday, down 7.57%, closing at $4.64. As well as the drop in value, Progenics Pharmaceuticals, Inc. hit a new 52 week low of $4.63, breaking the previous low of $4.68 from earlier this August. Two technical ‘scores’ for stocks to be wary of are the Altman Z1 and the Piotroski2 scores. PGNX scored quite low for both, which could be indicators of trouble down the road (the Altman Z-Score is -3.78, and the Piotroski Score is 0).

PGNX was outperformed by the rest of the Healthcare sector which went down only 2.30%.

Market Sectors

The market sectors were mixed Wednesday with a majority of the sectors trending down. Utilities saw the biggest increase of the day (0.15%), while Financials saw the biggest drop (4.40%). Healthcare has seen the biggest year-to-date gain at 13%. The biggest loss this year has been the Communication Services sector falling 13%.

Utilities saw the biggest turnaround from its 5-day performance of 2.31%, as it went up 0.15%. Industrials and Consumer Discretionary both saw turn arounds from their five day positive performance, Industrials with a drop of 4.35%.

Sector Breakdown

  • Utilities went up with a 0.15% change.
  • Real Estate went down with a -1.26% change.
  • Consumer Staples went down with a -1.63% change.
  • Healthcare went down with a -2.30% change.
  • Energy went down with a -2.93% change.
  • Materials went down with a -3.08% change.
  • Communication Services went down with a -3.14% change.
  • Information Technology went down with a -3.86% change.
  • Consumer Discretionary went down with a -3.91% change.
  • Industrials went down with a -4.35% change.
  • Financials went down with a -4.40% change.

Progenics Pharmaceuticals, Inc. Info

Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness adult patients receiving palliative care when laxative therapy has not been sufficient; and Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.

All amounts in USD unless otherwise indicated

(1) The Altman Z-Score calculation was first published in 1968 by Edward I. Altman, and is used for predicting the probability that a firm will go into bankruptcy within two years. An Altman Z-Score below 1.8 (Remember that Progenics Pharmaceuticals, Inc.’s score is -3.78) is the trigger to be alert for this situation. Some analysts believe this score is less relevant for some companies, in particular companies operating to accumulate users that may run at huge losses to scale up.

(2) The Piotrosky score is used to determine the best value stocks with nine being the best and zero being the worst. It is based on specific aspects of the company’s financial statements, such as positive net income, operating cash flow and asset turnover ratio. A score 0 0 is the worst (Progenics Pharmaceuticals, Inc.’s score is 0), and 9 is the best.

PGNX daily update

PGNX daily update
PGNX daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.

This site uses Akismet to reduce spam. Learn how your comment data is processed.